<DOC>
	<DOCNO>NCT00268996</DOCNO>
	<brief_summary>IBIS-2 study use SB-480848 versus placebo subject angiographically document coronary heart disease . Endpoints include coronary imaging , endothelial function , biomarkers , safety tolerability .</brief_summary>
	<brief_title>Integrated Biomarker And Imaging Study - 2</brief_title>
	<detailed_description>Integrated Biomarker Imaging Study -2 ( IBIS-2 ) : An International , Multicenter , Randomized , Placebo-controlled , Parallel-group , 1 Year Treatment , Integrated Biomarkers Imaging Study Subjects Angiographically Documented Coronary Heart Disease ( CHD ) Examine Effects Novel Lipoprotein-associated Phospholipase A2 ( Lp-PLA2 ) inhibitor SB-480848 Intermediate Cardiovascular Endpoints , Patient Safety Tolerability .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Inclusion criterion : Successful PCI ( Percutaneous Coronary Intervention ) uncomplicated diagnostic catheterization Suitable nonintervened coronary artery IVUS Antiplatelet therapy Exclusion criterion : Clinical instability Previous CABG ( Coronary Artery Bypass Graft ) surgery Planned major surgery Recent stroke Abnormal QTc Renal hepatic impairment Uncontrolled hypertension Use corticosteroid Class III IV heart failure Asthma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Lipoprotein-associated Phospholipase A2</keyword>
	<keyword>palpography</keyword>
	<keyword>hs-CRP</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>endothelial function</keyword>
	<keyword>intravascular ultrasound</keyword>
</DOC>